Switzerland’s Sandoz Takes Legal Action Against Amgen, Alleging Antitrust Violations in the US
Basel, Switzerland – Sandoz, a division of Swiss pharmaceutical giant Novartis AG, has launched an antitrust lawsuit against Amgen Inc. in the United States, accusing the American biotechnology firm of engaging in anti-competitive practices. The legal action, filed in the U.S. District Court for the Eastern District of Pennsylvania, alleges that Amgen has been blocking biosimilar competition to its white blood cell-boosting drugs, Neulasta and Neupogen, thus monopolizing the market. Sandoz argues that Amgen has set up a series of obstacles – ranging from questionable patents to exclusionary contracts with healthcare providers – effectively stifling … Read more